Clinical trials
Phase 1 clinical trials
Below are recruiting phase 1 clinical trials, each written for real people, not researchers. We’re tracking 285 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06232434RecruitingPhase 2/Phase 3
New gel treatment for advanced stomach cancer that has spread
This trial tests a new gel called Prospidelong given once into the abdomen during surgery for stomach cancer that has spread to the lining of the belly. The goal is to see if it is safe and works well.
Minsk, Minsk CityAges 18–75 - NCT06077838Recruiting
RELAXaHEAD app test for migraine relief
This study tests a smartphone app called RELAXaHEAD that teaches relaxation techniques to help people with migraine. If you have 4–29 headache days per month and haven't tried relaxation therapy for headaches recently, this app might help reduce your symptoms.
New York, New YorkAges 16–80 - NCT07364513RecruitingPhase 1
Safety study of IMSB301 for type 1 interferon disorders
This study tests an experimental drug (IMSB301) for people with rare genetic conditions that cause too much type 1 interferon activity (a part of the immune system). The goal is to see if the drug is safe and can help reduce symptoms.
SydneyAges 12 years+ - NCT07322445Recruiting
Study of neck and shoulder pain with special MRI
This study uses special MRI scans to look at muscles and nerves in people with long-term neck or shoulder pain caused by trigger points (tender spots in muscles). The goal is to understand what happens in the body with this type of pain—so doctors can find better ways to treat it.
St Louis, MissouriAges 18–80 - NCT05155033RecruitingPhase 2
A trial of PD-1 plus aldesleukin for melanoma or kidney cancer
This Phase 2 study tests whether combining anti–PD-1 treatment with aldesleukin can shrink or control metastatic melanoma or metastatic kidney (renal cell) cancer. It is mainly for people who have either not had anti–PD-1 before, or whose cancer did not respond to prior anti–PD-1 treatment.
Bethesda, MarylandAges 18–120 - NCT07263438RecruitingPhase 2
Trimipramine, atezolizumab, and bevacizumab for recurrent glioblastoma
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Basel, BaselAges 18 years+ - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT05508464Recruiting
Test targeted radiation to control many metastases safely
This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.
London, OntarioAges 18 years+ - NCT06839235RecruitingPhase 1/Phase 2
Testing ABO-101 for primary hyperoxaluria type 1
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
Rochester, MinnesotaAges 6–64 - NCT05795036Recruiting
Fitbit and text tips to boost walking after heart rehab
This study tests whether a phone-based program (Fitbit plus text messages and calls) helps people walk more during Phase III cardiac rehabilitation. It may help you build safer, healthier physical activity as part of your recovery plan.
Orlando, FloridaAges 18–99 - NCT07412821Enrolling by invitationPhase 1
Study of ASA-001 for ADSS1 deficiency muscle disease
This trial tests a drug called ASA-001 (adenylosuccinic acid) for people with a rare genetic muscle disease caused by ADSS1 deficiency. The goal is to see if it is safe and helps muscle function.
Los Angeles, CaliforniaAges 18 years+ - NCT06185764RecruitingPhase 1/Phase 2
VX-670 for adults with myotonic dystrophy type 1
This trial tests an experimental drug called VX-670 for adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. It aims to see if the drug is safe and can help improve symptoms.
San Carlos, CaliforniaAges 18–64 - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT07277764RecruitingPhase 2
Radiation and immunotherapy for returning nasopharyngeal cancer
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Nanchang, JiangxiAges 18–75 - NCT06542939Enrolling by invitation
Telehealth for diabetes and hypertension in South Asians
This study tests a telehealth program to help South Asian adults manage both diabetes and high blood pressure. If you have these conditions and your blood pressure is not well controlled, this program could help you improve your health from home.
New York, New YorkAges 21 years+ - NCT06282315RecruitingPhase 3
Safety of a new deworming pill for children in Ghana and Kenya
This trial tests how safe and effective a combined albendazole and ivermectin pill is for treating parasitic infections. It is for school-aged children in specific areas of Ghana and Kenya.
Accra, AccraAges 5–17 - NCT06942143RecruitingPhase 1
Super1 TCR-T for NY-ESO-1 positive advanced solid tumors
This trial tests an experimental treatment called Super1 TCR-T, which is a type of immunotherapy designed to attack tumors that have a specific protein (NY-ESO-1). It is for people with advanced solid tumors whose first treatment has stopped working and who also have a certain genetic marker (HLA-A*02).
Guangzhou, GaungdongAges 18–75 - NCT07199946RecruitingPhase 1/Phase 2
Verapamil to protect insulin production in children with new type 1 diabetes
This study tests if verapamil (a common blood pressure medication) can help children newly diagnosed with type 1 diabetes keep making their own insulin for longer. It aims to preserve the body's own insulin-producing cells, which may reduce the amount of insulin injections needed.
JönköpingAges 4–9 - NCT06890221Recruiting
Nutrition therapy before and after breast cancer surgery
This trial tests if a special nutrition drink before and after mastectomy can help breast cancer patients recover better. It uses a body measurement called bioimpedance phase angle to see how nutrition affects your cells and healing.
Petaling Jaya, Kuala LumpurAges 18 years+ - NCT06151587RecruitingPhase 3
Eye drop to slow myopia in children
This study tests an eye drop (QLM3004) to see if it can slow down the progression of nearsightedness (myopia) in children. It might be a good option if your child is between 6 and 12, has mild to moderate nearsightedness, and hasn't used other myopia treatments before.
Wenzhou, ZhejiangAges 6–12 - NCT06960213RecruitingPhase 3
Study of ADX-324 for preventing HAE attacks
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
Litchfield Park, ArizonaAges 18 years+ - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT06729242Recruiting
How menstrual cycle phases affect exercise and blood sugar in type 1 diabetes
This study looks at how the menstrual cycle changes the way your body responds to aerobic exercise or high-intensity interval training (HIIT) when you have type 1 diabetes. It may help you understand the best time to exercise for better blood sugar control.
Valencia, Select OneAges 18–45 - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+
Hear when a new Phase 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 1?
- Yes. Clin2 currently lists 285 recruiting phase 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.